Overview

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Status:
Withdrawn

Trial end date:
2022-09-29

Target enrollment:

Participant gender:

Summary

This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC. Both intermediate risk and BCG-unresponsive NMIBC participants will be included.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

H3 Biomedicine Inc.

Treatments:

Interferons